166 related articles for article (PubMed ID: 19091718)
21. Clinical characteristics of patients with cerebellar ataxia associated with anti-GAD antibodies.
Aguiar TS; Fragoso A; Albuquerque CR; Teixeira PF; Souza MV; Zajdenverg L; Alves-Leon SV; Rodacki M; Lima MA
Arq Neuropsiquiatr; 2017 Mar; 75(3):142-146. PubMed ID: 28355320
[TBL] [Abstract][Full Text] [Related]
22. Selective loss of Purkinje cells in a patient with anti-glutamic acid decarboxylase antibody-associated cerebellar ataxia.
Ishida K; Mitoma H; Wada Y; Oka T; Shibahara J; Saito Y; Murayama S; Mizusawa H
J Neurol Neurosurg Psychiatry; 2007 Feb; 78(2):190-2. PubMed ID: 17119008
[TBL] [Abstract][Full Text] [Related]
23. Cerebellar ataxia and glutamic acid decarboxylase antibodies: immunologic profile and long-term effect of immunotherapy.
Ariño H; Gresa-Arribas N; Blanco Y; Martínez-Hernández E; Sabater L; Petit-Pedrol M; Rouco I; Bataller L; Dalmau JO; Saiz A; Graus F
JAMA Neurol; 2014 Aug; 71(8):1009-16. PubMed ID: 24934144
[TBL] [Abstract][Full Text] [Related]
24. A patient with type 1 diabetes mellitus and cerebellar ataxia associated with high titer of circulating anti-glutamic acid decarboxylase antibodies.
Iwasaki H; Sato R; Shichiri M; Hirata Y
Endocr J; 2001 Apr; 48(2):261-8. PubMed ID: 11456277
[TBL] [Abstract][Full Text] [Related]
25. Presynaptic inhibition of cerebellar GABAergic transmission by glutamate decarboxylase autoantibodies in progressive cerebellar ataxia.
Takenoshita H; Shizuka-Ikeda M; Mitoma H; Song S; Harigaya Y; Igeta Y; Yaguchi M; Ishida K; Shoji M; Tanaka M; Mizusawa H; Okamoto K
J Neurol Neurosurg Psychiatry; 2001 Mar; 70(3):386-9. PubMed ID: 11181864
[TBL] [Abstract][Full Text] [Related]
26. Anti-GAD antibodies and periodic alternating nystagmus.
Tilikete C; Vighetto A; Trouillas P; Honnorat J
Arch Neurol; 2005 Aug; 62(8):1300-3. PubMed ID: 16087772
[TBL] [Abstract][Full Text] [Related]
27. Spectrum of neurological syndromes associated with glutamic acid decarboxylase antibodies: diagnostic clues for this association.
Saiz A; Blanco Y; Sabater L; González F; Bataller L; Casamitjana R; Ramió-Torrentà L; Graus F
Brain; 2008 Oct; 131(Pt 10):2553-63. PubMed ID: 18687732
[TBL] [Abstract][Full Text] [Related]
28. Selective suppression of cerebellar GABAergic transmission by an autoantibody to glutamic acid decarboxylase.
Ishida K; Mitoma H; Song SY; Uchihara T; Inaba A; Eguchi S; Kobayashi T; Mizusawa H
Ann Neurol; 1999 Aug; 46(2):263-7. PubMed ID: 10443895
[TBL] [Abstract][Full Text] [Related]
29. Glutamic acid decarboxylase autoantibodies and neurological disorders.
Vianello M; Tavolato B; Giometto B
Neurol Sci; 2002 Oct; 23(4):145-51. PubMed ID: 12536283
[TBL] [Abstract][Full Text] [Related]
30. Anti-GAD Antibody, Seizures, Cerebellar Ataxias and Vitiligo: A Diagnostic Challenge.
Flores-Cantu H; Camara-Lemarroy CR; Calderon-Hernandez HJ; Zapata-Rivera MA; Villareal-Perez JZ; Villareal-Velazquez HJ
Cerebellum; 2015 Jun; 14(3):375-7. PubMed ID: 25575726
[No Abstract] [Full Text] [Related]
31. Prevalence of Autoantibodies and the Efficacy of Immunotherapy for Autoimmune Cerebellar Ataxia.
Nanri K; Okuma M; Sato S; Yoneda M; Taguchi T; Mitoma H; Yamada J; Unezaki S; Nagatani T; Otsubo S; Sugawara M; Tanaka N; Mizusawa H
Intern Med; 2016; 55(5):449-54. PubMed ID: 26935362
[TBL] [Abstract][Full Text] [Related]
32. Responses to and Outcomes of Treatment of Autoimmune Cerebellar Ataxia in Adults.
Jones AL; Flanagan EP; Pittock SJ; Mandrekar JN; Eggers SD; Ahlskog JE; McKeon A
JAMA Neurol; 2015 Nov; 72(11):1304-12. PubMed ID: 26414229
[TBL] [Abstract][Full Text] [Related]
33. Rapidly progressing cerebellar ataxia associated with anti-GAD antibodies.
Quintas S; Ruiz RL; Zapata-Wainberg G; Vivancos J
Neurologia (Engl Ed); 2018 May; 33(4):273-275. PubMed ID: 27091680
[No Abstract] [Full Text] [Related]
34. Anti-glutamic acid decarboxylase limbic encephalitis without epilepsy evolving into dementia with cerebellar ataxia.
Mirabelli-Badenier M; Morana G; Pinto F; Uccelli A; Veneselli E; Battaglia FM; Biancheri R; Baglietto MG; Vincent A; Mancardi MM
Arch Neurol; 2012 Aug; 69(8):1064-6. PubMed ID: 22507885
[TBL] [Abstract][Full Text] [Related]
35. Vertical nystagmus associated with glutamic acid decarboxylase antibodies responding to cyclophosphamide.
Baizabal-Carvallo JF; Alonso-Juarez M
J Neuroimmunol; 2018 Apr; 317():5-7. PubMed ID: 29501085
[TBL] [Abstract][Full Text] [Related]
36. Transient Neurological Symptoms Preceding Cerebellar Ataxia with Glutamic Acid Decarboxylase Antibodies.
Muñiz-Castrillo S; Vogrig A; Joubert B; Pinto AL; Gonçalves D; Chaumont H; Rogemond V; Picard G; Fabien N; Honnorat J
Cerebellum; 2020 Oct; 19(5):715-721. PubMed ID: 32592031
[TBL] [Abstract][Full Text] [Related]
37. Cerebellar ataxia and epilepsy with anti-GAD antibodies: treatment with IVIG and plasmapheresis.
Georgieva Z; Parton M
BMJ Case Rep; 2014 Jan; 2014():. PubMed ID: 24419643
[TBL] [Abstract][Full Text] [Related]
38. Intravenous immunoglobulin therapy for autoantibody-positive cerebellar ataxia.
Nanri K; Okita M; Takeguchi M; Taguchi T; Ishiko T; Saito H; Otsuka T; Mitoma H; Koizumi K
Intern Med; 2009; 48(10):783-90. PubMed ID: 19443972
[TBL] [Abstract][Full Text] [Related]
39. Autoantibody screening in subacute cerebellar ataxia.
Trivedi R; Mundanthanam G; Amyes E; Lang B; Vincent A
Lancet; 2000 Aug; 356(9229):565-6. PubMed ID: 10950237
[TBL] [Abstract][Full Text] [Related]
40. Anti-contactin-associated protein-like 2 antibody-associated cerebellar ataxia: A case report and literature review.
Wang J; Qiu Z; Li D; Dong H; Hao J; Liu Z
J Neuroimmunol; 2021 Apr; 353():577515. PubMed ID: 33640718
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]